Advertisement
Advertisement

EXAS

EXAS logo

Exact Sciences Corp

103.17
USD
Sponsored
+0.52
+0.50%
Feb 06, 15:55 UTC -5
Closed
exchange

After-Market

103.17

0.00
0.00%

EXAS Earnings Reports

Positive Surprise Ratio

EXAS beat 30 of 40 last estimates.

75%

Next Report

Date of Next Report
Feb 24, 2026
Estimate for Q4 25 (Revenue/ EPS)
$878.11M
/
-$0.06
Implied change from Q3 25 (Revenue/ EPS)
+3.22%
/
-40.00%
Implied change from Q4 24 (Revenue/ EPS)
+23.08%
/
-98.72%

Exact Sciences Corp earnings per share and revenue

On Nov 03, 2025, EXAS reported earnings of -0.10 USD per share (EPS) for Q3 25, missing the estimate of -0.07 USD, resulting in a -40.06% surprise. Revenue reached 850.74 million, compared to an expected 826.38 million, with a 2.95% difference. The market reacted with a +3.90% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 25 analysts forecast an EPS of -0.06 USD, with revenue projected to reach 878.11 million USD, implying an decrease of -40.00% EPS, and increase of 3.22% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Amgen Inc
Report Date
Feb 03, 2026 For Q4 25
Estimate
$4.82
Actual
$5.29
Surprise
+9.56%
logo
Bristol-Myers Squibb Co.
Report Date
Feb 05, 2026 For Q4 25
Estimate
$1.12
Actual
$1.26
Surprise
+11.88%
logo
GSK plc - ADR
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.23
Actual
$0.49
Surprise
+111.36%
logo
Biogen Inc. Common Stock
Report Date
Feb 06, 2026 For Q4 25
Estimate
$1.62
Actual
$1.99
Surprise
+22.39%
logo
Illumina Inc
Report Date
Feb 05, 2026 For Q4 25
Estimate
$1.24
Actual
$1.35
Surprise
+8.01%
logo
QIAGEN N.V.
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.64
Actual
$0.62
Surprise
-3.32%
logo
Bio-Techne Corp.
Report Date
Feb 04, 2026 For Q2 26
Estimate
$0.44
Actual
$0.46
Surprise
+3.95%
logo
Arrowhead Research Corporation
Report Date
Feb 05, 2026 For Q1 26
Estimate
$0.25
Actual
$0.22
Surprise
-14.76%
logo
Immunovant, Inc. Common Stock
Report Date
Feb 06, 2026 For Q3 26
Estimate
-$0.72
Actual
-$0.61
Surprise
+16.27%
logo
Adaptive Biotechnologies Corporation Common Stock
Report Date
Feb 05, 2026 For Q4 25
Estimate
-$0.18
Actual
-$0.09
Surprise
+51.33%
FAQ
For Q3 2025, Exact Sciences Corp reported EPS of -$0.10, missing estimates by -40.06%, and revenue of $850.74M, 2.95% above expectations.
The stock price moved up 3.9%, changed from $66.98 before the earnings release to $69.59 the day after.
The next earning report is scheduled for Feb 24, 2026.
Based on 25 analysts, Exact Sciences Corp is expected to report EPS of -$0.06 and revenue of $878.11M for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement